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Abstract : Background : Enforcement of the 2018 Clinical Trials Act (CTA) in Japan resulted in strict and com-
plicated regulations surrounding intervention studies. Few Japan-specific measures have been developed to 
promote intervention studies in Japan despite concerns about CTA’s negative influence on such studies. There-
fore, this study examined the changes in academic investigators’ interest in conducting clinical studies before 
and after enforcement of the CTA to determine measures to promote specified clinical trials. Methods : We con-
ducted a questionnaire survey with investigators belonging to the Institute of Biomedical Sciences, Tokushima 
University Graduate School, before and after enforcement of the CTA. Results : Investigators had lesser interest 
in intervention studies in the post-questionnaire survey (post) group than in the pre-questionnaire survey (pre) 
group. Their desire for “project management” was significantly higher in the post-group than in the pre-group. 
Their desire for “support for preparing documents when conducting specified clinical trials” was significantly 
higher in the group interested in conducting specified clinical trials than that in the not-interested group. Con-
clusion : We revealed that investigators were highly interested in “project management” and “support for pre-
paring documents when conducting specified clinical trials” after enforcement of the CTA. Measures for these 
desires may promote specified clinical trials. J. Med. Invest. 68 : 71-75, February, 2021
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INTRODUCTION
 
In April 2018, the Clinical Trials Act (CTA) was enforced 
in Japan as a regulation for cases of misconduct, such as the 
Valsartan case wherein scientific misconduct and inappropriate 
relationship between academia and companies were identified 
(1). The Valsartan case involved the arrest of an employee of a 
company that marketed Valsartan by manipulating data from 
clinical trials conducted by medical and research institutions. 
The CTA aims to prevent such cases of scientific misconduct 
by enforcing improvements or discontinuation of clinical trials, 
which is otherwise not possible under the “Ethical Guidelines 
for Medical and Health Research Involving Human Subjects” in 
Japan (1-3). When investigators conduct clinical trials to clarify 
the efficacy or safety of pharmaceuticals, medical devices, or 
regenerative products (“pharmaceuticals,” hereafter) in humans, 
such trials are subject to CTA (3). If they use unapproved/
off-label pharmaceuticals or receive research funding from a 
manufacturer with marketing approval for pharmaceuticals, the 
clinical trial is categorized as a specified clinical trial. Interven-
tion studies, which account for most of the clinical studies, are es-
sential to develop medicine and thus must be promoted under the 
CTA. Nakamura reported that there have been concerns about 
negative influences of the CTA’s strict and complicated regula-
tions on intervention studies that reduce clinical trial activity in 
Japan (4). Moreover, in Japan, fewer intervention studies may 
be conducted due to the CTA in the future (4). Previous studies 
show that the number of clinical trials decreased remarkably 
when the EU directive was introduced in 2004 (5, 6). 
The CTA regulations are similar to the Good Clinical Practice 
standards of the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for 
Human Use, which are the regulatory cornerstone of CTA. Nev-
ertheless, there is a need for studies that consider Japan-specific 
issues—such as the certified review board (CRB)’s review fee, 
conflict of interest management plan, and registration at the 
Japan Registry of Clinical Trials (jRCT ; a newly established 
clinical trial registry website)—for promoting clinical studies (1, 
3). Moreover, which Japan-specific measures are necessary to 
promote specified clinical trials that must be conducted under 
the CTA remains unknown.
In Japan, the main role of the academic research organiza-
tions (AROs) is promoting clinical research. AROs with full 
functions that provide a sufficient management system for 
performing clinical study and promote clinical trials under reg-
ulation of Good Clinical Practice are approved as core clinical 
trial hospitals by the Ministry of Health, Labour and Welfare 
(7). However, there are 13 organizations that have an ARO with 
full functions (as of April 1, 2020) ; they represent only 0.16% 
(13 / 8255) of the total 8,255 hospitals in Japan, of which 11 are 
university hospitals (8, 9). There are also 98 CRBs, and 68 of 
them are located at universities / university hospitals. Thus, 
since most universities/university hospitals with CRBs (83.8%, 
57 / 68) have AROs without full functions, it is important to 
examine measures that can promote clinical research among 
researchers at these organizations in order to facilitate specified 
clinical trials. The aim of this study was to evaluate the desire 
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and interests of investigators at The Tokushima University (one 
of the institutions with CRBs but AROs without full functions) 
regarding the support of clinical research and to determine the 
impact of CTA implementation at an institution with inadequate 
support for clinical research.
METHODS
Questionnaire distribution and interests identified through the 
survey
We utilized a questionnaire survey to examine the changes 
in the interest in conducting clinical studies before and after 
CTA’s implementations. The survey was conducted with in-
vestigators belonging to the Institute of Biomedical Sciences, 
Tokushima University Graduate School, because this institu-
tion does not have an ARO but has a CRB. Five questionnaire 
sheets were distributed to all departments before and after 
enforcement of CTA (pre-group : pre-questionnaire survey, 30 
departments ; post-group : post-questionnaire survey, 33 depart-
ments), wherein at least five full-time physicians and dentists 
who mainly conduct intervention studies at Tokushima Univer-
sity are enrolled (pre-group : total 150 sheets ; post-group : total 
165 sheets). Four faculty members were consulted to obtain 
details about the respondents’ interest in promoting specified 
clinical trials, and we asked academic investigators who usu-
ally conduct clinical trials and clinical research to answer the 
questionnaires as much as possible. The questionnaire asked 
about the investigators’ characteristics such as gender, position, 
experience with clinical trials, ethics committee applications, 
interest in each study design, and desire for human and physical 
resources required for the smooth promotion of clinical research. 
Many research organizations with AROs without full functions 
have evolved to support industry-initiated clinical trials, but are 
presumably not well-equipped to promote academia-initiated 
clinical research by their investigators (10, 11). Since this feature 
is considered to be common to research organizations without 
AROs with full functions, the desires and interests considered 
necessary to promote research in these organizations were de-
termined for various occupations (physician, pharmacist, nurse, 
and nutritionist) and departments. 
We arranged for biostatisticians and faculty members (cur-
rent faculty members : two physicians and two pharmacists) 
and focused on educational opportunities across the pre- and 
post-questionnaire surveys (Figure 1). The pre-questionnaire 
survey assessed interest / desire for opportunities for education 
when conducting a clinical study. The post-questionnaire survey 
identified two interests—(1) support for preparing documents 
when conducting specified clinical trials and (2) establishment 
of a fund for conducting specified clinical trials. This is because 
these interests were required to support application documents 
and obtain funding after the CTA. The pre- and post-question-
naire surveys both identified six common interests—(1) project 
management, (2) academic office for promoting clinical study, (3) 
support for conducting clinical study, (4) data management, (5) 
electronic data capture, and (6) quality control. 
Statistical analysis
Data were presented as rates and percentages of the respon-
dents. The p-value of < 0.05 was considered to be statistically 
significant.
RESULTS
Characteristics of the respondents
The response rate for the pre-questionnaire survey was 70.7 % 
(106/150) and that for the post-questionnaire survey was 75.2% 
(124/165) ; there was no significant difference in the two groups 
(Table 1). In these two groups, most respondents were at the 
position of non-professor (pre-group : 81.1%, post-group : 76.6%), 
followed by professor (pre-group : 15.1%, post-group : 15.3%). In 
both groups, more than 90% of respondents were research fac-
ulty members and had experience of clinical trials or application 
Figure 1.　Events and interventions to promote clinical studies before and after implementation of the Clinical Trials Act (CTA)
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to an ethics committee. Thus, investigators who usually conduct 
clinical studies and clinical trials accounted for the majority 
of respondents, suggesting that we obtained the response from 
investigators that we expected. In the post-group, the interest in 
intervention study was significantly lower than that in the pre-
group (pre-group : 50.0%, post-group : 34.7%), although there 
was no significant difference between the two groups in expe-
rience of clinical trials, application to an ethics committee, and 
interest in observational study. This suggests that investigators’ 
interest in intervention studies decreased after enforcement of 
the CTA.
Comparison of investigators’ interest in conducting clinical studies 
before and after enforcement of the CTA
A comparison of the six interests common to both groups 
showed that investigators’ interest in “project management” in 
the post-questionnaire survey was significantly higher than 
that in the pre-questionnaire survey (pre : 51.9%, post : 71.8%), 
suggesting that their interest in conducting clinical studies was 
increasing. As expected, the investigators responded highly 
( ≥ 70%) to “support for preparing documents when conducting 
specified clinical trials” (86.3%) and “establishment of a fund 
when conducting specified clinical trials” (79.8%), which were 
added in the post-questionnaire survey. Similarly, there was 
high interest in “support for conducting a clinical study” (75.0%) 
and “project management” (71.8%).
Comparison of investigators’ interest in conducting specified clini-
cal trials
We compared the desire for conducting clinical studies among 
investigators who were interested in conducting specified clini-
cal trials (interested group : 63) and those who were not (not-in-
terested group : 61). This is because the post-group’s interest 
in intervention studies was significantly lower than in the pre-
group (Table 2). Approximately 50% (63/124) of respondents 
(interested group) desired to conduct specified clinical trials. 
Moreover, the interested group’s rate of interest in intervention 
studies (46%) was significantly higher than that of the not-inter-
ested group (23%). This suggests that the interest in specified 
clinical trials is related to an interest in intervention studies. 
The interested group favored “support for preparing documents 
when conducting specified clinical trials” (96.8%) significantly 
more than the not-interested group (75.4%). Moreover, more 
than 70% of respondents in both groups were generally interest-
ed in “establishment of a fund when conducting specified clinical 
trials,” “support for conducting a clinical study,” and “support for 
preparing documents when conducting specified clinical trials.”
 
Comparison of investigators’ interest in conducting specified clini-
cal trials between participants and non-participants groups
We classified the pre-group into two groups—participation 
group and non-participation group—to examine investigators’ 
Table 1.　Comparison of investigators’ interest in conducting clinical studies before and after implementation of the Clinical Trials Act (CTA). 
Data are presented based on the number of respondents (rates and percentages).
Questionnaire survey
P value
pre (n=106) post (n=124)
Response rate (%) 70.7 75.2 0.377
Gender (male / female) 92 / 14 98 / 26 0.162
Position 0.376
Director / professor 16 (15.1) 19 (15.3)
Faculty other than professor 86 (81.1) 95 (76.6)
Medical staff 1 (0.94) 6 (4.84)
Graduate student 1 (0.94) 3 (2.42)
Other 2 (1.89) 1 (0.81)
Experience of performing clinical trial 72 (67.9) 71 (57.3) 0.104
Experience of application to an ethics committee 91 (85.9) 107 (86.3) 0.104
Interest in clinical study
Intervention study 53 (50.0) 43 (34.7) 0.023
Observational study 68 (64.2) 92 (74.2) 0.115
Neither 0 (0.0) 1 (0.81) 1.000
Desire for a support system for conducting clinical study
Project management 55 (51.9) 89 (71.8) 0.003
Academic office for promoting clinical study 53 (50.0) 77 (62.1) 0.083
Support for conducting clinical study (e.g., informed consent and schedule management) 71 (67.0) 93 (75.0) 0.191
Data management 77 (72.6) 86 (69.4) 0.663
Electronic data capture 56 (52.8) 70 (56.5) 0.597
Quality control (e.g., monitoring and audit) 52 (49.1) 70 (56.5) 0.29
Opportunity for education when conducting a clinical study 49 (46.2) -
Support for preparing documents when conducting specified clinical trials 107 (86.3)
Establishment of a fund in conducting specified clinical trials 99 (79.8)
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interest, because participation in workshops on CTA is likely 
to affect the interests/desire of the investigators. Interest in 
conducting intervention study among workshop participants 
was higher than that among non-participants. On the other 
hand, the eight items related to supporting performing clinical 




In Japan, there is a concern that implementation of the CTA in 
2018 may reduce the number of intervention studies conducted. 
Therefore, unique measures that promote specified clinical trials 
to support investigators are required, because the CTA is differ-
ent from international regulations. In this study, we conducted 
a questionnaire survey before and after enforcement of the CTA 
to understand the investigators’ interest in conducting specified 
clinical trials and to determine the basis of measures to promote 
specified clinical trials. Among the four items that investigators 
were highly interested in after enforcement of the CTA—“project 
management,” “support for conducting a clinical study,” “support 
for preparing documents when conducting specified clinical 
trials,” and “establishment of a fund when conducting specified 
clinical trials”—investigators’ interest in “project management” 
in the post-group was significantly higher than that in the pre-
group. Similarly, among the three items in which investigators 
of both interested and not-interested groups classified from the 
post-group were highly interested in—“establishment of a fund 
when conducting specified clinical trials,” “support for conduct-
ing a clinical study,” and “support for preparing documents when 
conducting specified clinical trials—the interest in “support 
for preparing documents when conducting specified clinical 
trials” was significantly higher in the interested group than 
in the not-interested group. A previous report showed that in 
Denmark, where support organizations provide free assistance 
to academic clinical researchers to promote clinical research, 
although the number of clinical trials declined after implementa-
tion of the 2004 European Clinical Trials Directive, this decline 
ended and then the number of clinical trials increased (12). This 
suggests that development of a support organization for clinical 
trials is necessary to promote interventional studies (12). In fact, 
it is necessary to create a seamless department in each organiza-
tion that is led by investigators who have experience in designing 
and publishing clinical trials (13). 
Moreover, we have previously reported the necessity to develop 
new guidelines for intervention trials (14) and to provide support 
to investigators conducting clinical studies under awareness of 
Table 2.　Comparison of investigators’ interest in conducting specified clinical trials. Data are presented as number of respondents (rates ; per-
cent).
Performing “specified clinical trials”
P value
Interested (n=63) Not interested (n=61)
Interest in intervention study 29 (46.0) 14 (23.0) 0.008
Desire for a support system for conducting clinical study
Project management 48 (76.2) 41 (67.2) 0.320
Academic office for promoting clinical study 42 (66.7) 35 (57.4) 0.355
Support for conducting clinical study 47 (74.6) 46 (75.4) 1.000
Data management 43 (68.3) 43 (70.5) 0.847
Electronic data capture 38 (60.3) 32 (52.5) 0.469
Quality control 39 (61.9) 31 (50.8) 0.277
Support for preparing documents when conducting specified clinical trials 61 (96.8) 46 (75.4) < 0.001
Establishment of a fund when conducting specified clinical trials 53 (84.1) 46 (75.4) 0.267
Table 3.　Comparison of investigators’ interest in conducting specified clinical trials between participant and non-participant groups. Data are 
presented as number of respondents (rates ; percent)
Participation in CTA workshop
P value
Yes (n=41) No (n=83)
Interest in conducting intervention study 20 (48.8) 23 (27.7) 0.027
Desire for a support system for conducting clinical study
Project management 29 (70.7) 60 (72.3) 1.000
Academic office for promoting clinical study 26 (63.4) 51 (61.5) 1.000
Support for conducting clinical study 34 (82.9) 59 (71.1) 0.189
Data management 28 (68.3) 58 (69.9) 1.000
Electronic data capture 25 (61.0) 45 (54.2) 0.565
Quality control 26 (63.4) 44 (53.0) 0.337
Support for preparing documents when conducting specified clinical trials 34 (82.9) 73 (88.0) 0.580
Establishment of a fund when conducting specified clinical trials 32 (78.1) 67 (80.7) 0.813
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the CTA through the following : arranging faculty members and 
biostatisticians, creating opportunities for education, promoting 
the establishment of an on-campus fund for conducting clinical 
studies, and preparing reference material for application docu-
ments when conducting specified clinical trials before enforce-
ment of the CTA (Figure 1) (11). We also provided support for the 
preparation of documents and consultation for designing clinical 
research such as through intervention and observational studies 
by making available four faculty members (two physicians and 
two pharmacists) before enforcement of the CTA. Results of the 
pre- and post-questionnaire surveys revealed that investigators 
highly desire “project management” and “support for preparing 
documents when conducting specified clinical trials.” Clinical 
Research Center for Developmental Therapeutics, Tokushima 
University Hospital has already begun supporting investiga-
tors belong to its research institution by providing “support for 
preparing documents when conducting specified clinical trials.” 
This is expected to contribute to the promotion of specified 
clinical trials, as these measures are based on the desires and 
interests identified in this study in addition to the previous 
efforts of preparing documents and providing consultation for 
the design of clinical research before enforcement of the CTA. 
In contrast, there were no significant differences in the level of 
desire between participants and non-participants in the work-
shop. Because the workshop was held immediately before and 
after the enforcement of the CTA, it was mainly focused on the 
overview and regulations of the CTA and was unable to focus 
on the promotion measures of specified clinical trials, which 
may have been one of the reasons. Since researchers interested 
in intervention study participated in the workshop, continued 
workshops with contents related to the promotion of clinical 
research would increase researchers’ understanding and desire 
for support of clinical research. Measures based on the interests 
of investigators belonging to research organizations that do not 
have AROs with full functions (which account for most organi-
zations in Japan) may lead to the development of a universal 
system to promote specified clinical trials. 
There are two limitations in this study. First, it conducted 
a questionnaire survey at a single organization. Inter-facility 
bias and excess or deficiency of the questionnaire’s survey items 
may affect the results. Second, biostatisticians and faculty 
members to promote clinical research were arranged across the 
pre- and post-questionnaire surveys, which may have influenced 
researchers’ desire for conducting clinical study in the question-
naire survey.
CONCLUSION
This study revealed that academic investigators are highly 
desirous of project management and support for drafting and 
editing the protocol after enforcement of the CTA. Measures 
that address these desires may promote specified clinical trials 
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